David Lee is a Gastroenterology physician. ClinicalTrials.gov lists 16 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
6900 L St Ste 1
Lincoln, NE 685102478
Telephone
402-441-5600Provider last certified this registry record 23 Dec 2021.
Clinical trials
- A Study to Evaluate the Tolerability, Safety, and PK of AST-201 in Patients With GPC3-positive Advanced Solid Tumors
Sponsor: Aptamer Sciences, Inc.
- Impact of Intraoperative ICG on Functional Outc in RARP
Sponsor: University of California, Irvine
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
22 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- ABBVIE INC.Program year20259 payments
- Janssen Biotech, Inc.Program year20257 payments
- Takeda Pharmaceuticals U.S.A., Inc.Program year20253 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
85.4%Proton pump inhibitor27.8%Omeprazole57%Pantoprazole Sodium37%Nexium6%Part D<11 patientsAminosalicylate23.9%Balsalazide Disodium27%Mesalamine26%Mesalamine Er23%Sulfasalazine17%Mesalamine Dr7%Part D<11 patients+ 10 more classes in this area
Cardiovascular
11.3%Bile Acid Sequestrant6.7%Colesevelam Hcl60%Colestipol Hcl40%Part D<11 patientsAldosterone antagonist (MRA)2.7%Spironolactone100%Part D<11 patients+ 1 more class in this area
Respiratory
1.7%Corticosteroid1.7%Budesonide Dr100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Similar KOLs
Other experts from the same institution or the same specialty.
Josep M. Llovet
Institució Catalana de Recerca i Estudis Avançats
Joseph J.�Y. Sung
Nanyang Technological University
Neeraj Bhala
The Royal Melbourne Hospital
Jordi Bruix
Hospital Clínic de Barcelona
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”